Market outlook for Asahi Kasei's TARPEYO in IgA Nephropathy therapeutics
A recent market report analyzes the role of Asahi Kasei's budesonide-based therapy TARPEYO in the evolving landscape of IgA nephropathy treatments.
A new industry analysis by DelveInsight evaluates the market trajectory of TARPEYO, a delayed-release budesonide formulation developed by Asahi Kasei and its subsidiary Calliditas Therapeutics. The drug is designed for targeted delivery in the lower small intestine to modulate the immune responses associated with IgA nephropathy, a condition that impairs kidney filtration.
The global market for IgA nephropathy treatments was valued at approximately USD 730 million in 2024. Projections indicate a robust annual growth rate of over 30 percent through 2034, driven by increasing diagnosis rates and the urgent clinical need to delay end-stage kidney disease. TARPEYO currently competes in a space that has traditionally relied on blood pressure management, such as ACE inhibitors and ARBs.
The therapeutic landscape is undergoing significant changes as new clinical candidates emerge. Major pharmaceutical entities, including Novartis and Vertex Pharmaceuticals, are advancing their own therapies for the condition. As these novel interventions enter the market, the commercial environment for IgA nephropathy treatments is expected to shift substantially.